



**Company Contact:**  
**Jie Du, Ph.D.**  
**President & CEO**  
**JDP THERAPEUTICS, INC.**  
**Email: [jiedu@jdptherapeutics.com](mailto:jiedu@jdptherapeutics.com)**  
**[www.jdptherapeutics.com](http://www.jdptherapeutics.com)**

## **Dr. Graham May Joins JDP Therapeutics as Chief Medical Officer**

**BLUE BELL, PENNSYLVANIA, October 12, 2012** – JDP Therapeutics Inc., a privately held clinical stage specialty pharmaceutical company, today announced that Graham May, M.D. has joined JDP Therapeutics as its Chief Medical Officer. Dr. May brings a wealth of Pharmaceutical experience expanding more than thirty years in clinical development, regulatory affairs, operation, etc., and has been responsible for multiple product approvals in a wide array of therapeutic areas. Prior to joining JDP Therapeutics, Dr. May was the Sr. Vice President & Chief Medical Officer at EKR Therapeutics, and prior to that he held executive positions at Esprit Pharma and ESP Pharma, all acute care specialty pharmaceutical companies that had a successful exit through strategic acquisition. Dr. May received undergraduate and medical degrees from Cambridge University and is an Elected Fellow of the Faculty of Pharmaceutical Physicians.

"We are delighted to have Dr. May join us as our Chief Medical Officer", said Jie Du, Ph.D., President and CEO at JDP Therapeutics. "Dr. May's deep clinical & medical expertise combined with his extensive leadership experience, represents a significant addition to our organization's capabilities. With Dr. May's addition to our team, we have great confidence in our ability to execute on our clinical development and aggressive growth objectives. We welcome Dr. May to the CMO role in the Company and look forward to his contribution to the future development of JDP".

### **About JDP Therapeutics Inc.**

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email [info@jdptherapeutics.com](mailto:info@jdptherapeutics.com)

###

*Safe Harbor Statement Regarding Forward-looking Statements*

*The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.*